

Портфолио на Рош за рак на маточната шийка
Да предоставим на жените информация, грижа и защитата, която заслужават, с помощта на портфолиото на Рош за рак на маточната шийка
Науката, която създава сигурност
Портфолиото на Рош за рак на маточната шийка е предназначено да идентифицира най-значимите показатели на заболяването, при скрининг на всички жени, независимо от възрастта. Нашите продукти предоставят на медицинските специалисти необходимите инструменти и решения за бързо и точно извършване на скринингови тестове за жени, предоставят ясни отговори на пациента, дават възможност за незабавен триаж за оптимална стратификация на риска от HPV и получаване на резултати, които да ръководят решенията за последваща грижа.
Резултатът? Жените, които разчитат на Вас, се възползват от най-добрата профилактика на рак на маточната шийка и грижите, които заслужават. Комплексното портфолио на Рош за рак на маточната шийка означава по-малко рискове от неоткрито заболяване или липса на лечение.
Медицинските специалисти получават повече информация, за да вземат в точния момент правилното решение за своите пациенти.

HPV и рак на маточната шийка
Бъдете информирани относно превенцията, скрининга и оптимизираните подходи за стратификация на риска

Стратегии за скрининг и триаж
Научете за възможните опции за управление на риска при пациенти, за да идентифицирате и предотвратите преканцерозата по-рано

Превенция на цервикален карцином
Научете за цялото портфолио на Roche за рак на маточната шийка, за по-добър скрининг, триаж и диагностика на цервикално заболяване
Danielle, a NYC based freelance writer for women's health, pop culture and relationships, Author of "The Semi-Scandalous Story of an Ex-Virgin", HPV #cervivor, and huge baseball fan, discusses cervical cancer prevention.
HPV tried to wreck Danielle's life, and took her on a scary journey to prevent cervical abnormalities from progressing into invasive cancer. Watch this video (Part 1 of 4) where Danielle explains the role of HPV and how unfair it is that women feel stigma around something so relatively common. To watch the rest of Danielle's stories, please click here.
A Clinician's Perspective on New Biomarker Technology to Assess Risk in Cervical Cancer Prevention
Dr. Nathalie Michaud meets with Danielle Sepulveres in San Francisco to give an update about what’s important to know about cervical cancer prevention. During this conversation, they discuss Pap cytology, HPV testing, and a new option to use advanced biomarker technology approved by the FDA in March 2020 for women with positive high-risk HPV screening results. Run from the same sample collected for Pap cytology or HPV testing, next generation biomarker cytology provides additional information that can help guide a clinician’s next step decisions for a patient.
“Whether [the biomarker test result] is positive or negative, you know what to do, and you don’t have to wait and worry” – Dr. Nathalie Michaud.
To view Danielle’s full clinician perspective video story, click here.
Over 80% of sexually active adults will get HPV at some point in their lives1
90% of HPV infections are cleared within 2 years2
Around the world, cervical cancer is one of the most common cancers in women3
70% of cervical cancers are caused by the two highest risk types, HPV 16 & HPV 184
Lorem ipsum
Lorem ipsum
Lorem ipsum
Lorem ipsum
HPV: A Link to Cervical Cancer
HPV is a common sexually transmitted infection, and most women will not know that they or their partners have it. HPV is most often spread through sexual intercourse. It can also be transmitted via non penetrative sexual activity.5
HPV is a small, double-stranded DNA virus that affects epithelial cells such as skin and mucous membranes. There are more than 150 HPV genotypes, about 30 of which are sexually transmitted. Most HPV strains are harmless; however, a handful of high-risk types cause infections that can develop into cervical cancer.
There are 14 high-risk HPV types that are detected in over 99% of cervical cancers.2,3 Two HPV types, HPV 16 and HPV 18, are associated with 70% of all cervical cancers.3 HPV 16 causes approximately 55% to 60% of cervical cancer cases, and HPV 18 accounts for 10% to 15%.2 Globally, genotypes HPV 16 and HPV 18 are more oncogenic and likely to progress to high grade cervical disease than all other high-risk HPV genotypes combined.6
Портфолиото на Рош за рак на маточната шийка е комплексно решение за скрининг, триаж и диагностика на цервикално заболяване.

Cervical Cancer Screening
-
When should I be screened for cervical cancer?
-
Could I get an HPV test as part of my exam?
-
If have been vaccinated for HPV, do I still need cervical cancer screening?
-
How often do you recommend I get an HPV test?
-
I want an HPV test that detects HPV 16 and 18, how do I get it?
-
If my results are positive, what is the next step?
-
Are there any brochures, websites or other materials that I can use to learn more about cervical cancer prevention?
General Health
-
Do I need any important shots?
-
How can I protect myself from HIV and other STDs?
-
Where can I get mental health help?
-
How can I get more physical activity?
-
What form of birth control is right for me?
-
How can I incorporate more healthy eating habits into my diet?
-
Given my family history, am I at a higher risk for certain diseases or illnesses?

Join our Facebook community
Know Your Risk for Cervical Cancer is a Facebook community dedicated to increasing women’s awareness and knowledge about HPV, its role in cervical cancer, the importance of screening tests, and connecting with other women. Join our community of more than 67,000 individuals dedicated to encouraging each other to be in control of their own health and wellness.